SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals (CRVS) is trending due to positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, which demonstrated significant efficacy and a favorable safety profile. The community is vigorously debating the stock's substantial surge, highlighting the drug's potential as a "best-in-class" oral therapy for a large market and speculating on future partnerships or a buyout. However, some investors express caution given the early-stage nature of the trial results and the historical tendency for Phase 1 catalysts to precede dilution.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market activity following a favorable FDA meeting for its ANKTIVA + BCG bladder cancer application, which did not require new clinical trials, de-risking its path forward. The community is actively discussing a potential short squeeze, fueled by exceptionally high trading volume and strong conviction in the company's transformative cancer therapies. Investors are showing "diamond hands" as they anticipate further positive developments and a re-rating of the stock's value, pushing back against perceived short seller pressure.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending intensely ahead of its upcoming earnings, with community sentiment highly polarized on whether strong content performance and recent strategic maneuvers, like the revised all-cash bid for Warner Bros. Discovery assets, will drive a significant rebound. Investors are closely debating the potential impact of these developments on subscriber growth and profitability, while also considering how broader market pressures and recent bond purchases by President Trump might influence the stock's post-earnings trajectory.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending amid news of the U.S. government establishing a new digital asset reserve by holding seized Bitcoin, a shift from prior selling policies. This development comes as the community intensely debates BTC's price volatility, questioning its "safe haven" status against surging gold and silver amidst broader market uncertainty and geopolitical tensions. Despite these short-term pressures, discussions highlight ongoing significant institutional and large-scale investor acquisitions.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is currently trending due to market reports indicating potential acquisition talks with Zydus Lifesciences, sparking widespread community discussion about a possible bidding war and future valuation. This comes on the heels of robust preliminary financial updates, including accelerated revenue projections for IBSRELA, now expected to reach a billion by 2029, and a significant patent extension to 2041 for its key products. Investors widely regard this extended intellectual property protection as a pivotal development, potentially driving a substantial re-rating and further M&A interest in the biotech sector.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending amid discussions of its strengthened position in the AI data center sector, following its recent full ownership of a key Texas data center campus and a strategic co-development partnership. The community is actively debating a potential short squeeze and eagerly awaiting an anchor tenant announcement for its hyperscale project, underscoring its perceived resilience despite past challenges.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as new institutional developments, such as NYSE's tokenized securities platform, fuel optimism for its long-term utility, alongside record-high staking demand and near-zero unstaking queues. Despite this, community discussions are polarized, with debates centered on whether current market downturns and liquidations represent a prime buying opportunity or signal further weakness amidst broader crypto market volatility.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk (TTD) is trending due to its persistent decline, consistently hitting multi-year lows despite a generally positive market, leading to widespread shareholder frustration and calls for management accountability. Community discussions are heavily focused on CEO Jeff Green's perceived inaction and competitive pressures from 'walled garden' advertising platforms like Amazon. Investors are now keenly awaiting upcoming earnings as a potential make-or-break catalyst for the stock's direction.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid escalating geopolitical concerns related to potential US-EU trade tariffs and discussions around Greenland, which are generating broad market uncertainty. The community is actively debating the implications, with traders engaged in high-volume options activity as broader indexes experience a sell-off alongside global bond market movements.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant licensing agreement with Pfizer for its Matrix-M adjuvant, validating the platform's potential and sparking widespread community discussion. This news, coupled with growing interest from other pharmaceutical companies, has heightened speculation of a short squeeze while also increasing pressure on management to deliver further strategic partnerships.

statis crypto Watchlist

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Brokerages

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven research firms that are covering the firm, MarketBeat.com reports. Two analysts...

CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eleven analysts that are covering the company, MarketBeat.com reports. Three equities...

Matthew Winton Buys 1,500 Shares of CervoMed (NASDAQ:CRVO) Stock

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) insider Matthew Winton purchased 1,500 shares of the company's stock in a transaction dated Tuesday, November 18th. The shares were bought at an average...

Sylvie Gregoire Purchases 1,707 Shares of CervoMed (NASDAQ:CRVO) Stock

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) Director Sylvie Gregoire purchased 1,707 shares of the firm's stock in a transaction on Friday, November 14th. The stock was acquired at an average cost...

Insider Buying: CervoMed (NASDAQ:CRVO) CEO Buys 1,707 Shares of Stock

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) CEO John Alam acquired 1,707 shares of the business's stock in a transaction on Friday, November 14th. The shares were bought at an average price of...

CervoMed (NASDAQ:CRVO) CEO John Alam Buys 4,447 Shares

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) CEO John Alam acquired 4,447 shares of CervoMed stock in a transaction on Thursday, November 13th. The stock was acquired at an average cost of $7.51 per...

CervoMed (NASDAQ:CRVO) Director Sylvie Gregoire Acquires 4,447 Shares

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) Director Sylvie Gregoire bought 4,447 shares of the company's stock in a transaction on Thursday, November 13th. The shares were acquired at an average...

CervoMed (NASDAQ:CRVO) Insider Matthew Winton Buys 10,000 Shares of Stock

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) insider Matthew Winton bought 10,000 shares of the business's stock in a transaction on Friday, November 14th. The stock was bought at an average price...

CervoMed (NASDAQ:CRVO) Insider Purchases $75,700.00 in Stock

CervoMed Inc. (NASDAQ:CRVO - Get Free Report) insider Matthew Winton purchased 10,000 shares of the firm's stock in a transaction dated Friday, November 14th. The stock was acquired at an average...

FY2025 EPS Estimates for CervoMed Cut by Chardan Capital

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Investment analysts at Chardan Capital dropped their FY2025 earnings estimates for CervoMed in a report released on Tuesday, November 11th. Chardan Capital...

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.

CRVO
CervoMed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVO News

CRVOCervoMed Inc